Publications by authors named "C Willekens"
Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy with limited therapeutic options. Single-cell analysis of clonal architecture demonstrates early clonal dominance with few residual WT hematopoietic stem cells. Circulating myeloid cells of the leukemic clone and the cytokines they produce generate a deleterious inflammatory climate.
View Article and Find Full Text PDFArticle Synopsis
- Circulating proteomes can reveal the body's response to diseases like COVID-19 and treatments like tocilizumab, which is used to mitigate severe symptoms.
- In a study involving 28 hospitalized COVID-19 patients treated with tocilizumab, researchers collected serum samples to analyze changes in protein levels before and after treatment and assessed patient outcomes for 30 days.
- Findings indicated that specific proteins related to the complement system and Fc-epsilon receptor signaling could predict treatment success and mortality, where high complement activation linked to worse outcomes and certain signaling pathways showed lower mortality rates.
Background: Early-phases clinical trials (Phases 1 and 2) have evolved from a traditional assessment of toxicity to an adaptive approach based on patients' medical needs and access to effective new therapies. The global risks, benefits, and relevance of early-phases clinical trials participation for patients with hematological malignancies remain poorly evaluated.
Patients And Methods: All early-phases clinical trials participations for patients with hematological malignancies, from 2008 to 2023, in a tertiary academic center in Europe, were reviewed.
Article Synopsis
- * These mutations vary in their effects based on specific types and can influence treatment efficacy and disease progression; they may not always work as independent prognostic indicators.
- * Research is ongoing into new therapies targeting the RAS pathway, with hope that advances seen in solid tumors will also benefit patients with blood cancers.